The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

The lower costs and convenience of a blood test could also help expand use of two new drugs, Leqembi and Kisunla, which have been shown to slightly slow the progression of Alzheimer's by clearing ...

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Australia just approved the first new Alzheimer’s treatment in decades. But before patients get their hopes up, there’s a ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

Eli Lilly’s Alzheimer’s treatment, Kisunla (donanemab), scored a major win with approval in Australia, marking it as the ...

A report found that the world's youngest Alzheimer's patient is actually a 19-year-old boy. He first started showing signs at ...

Eli Lilly has received approval in Australia to market its Alzheimer's treatment Kisunla. The pharmaceutical company said Wednesday the Australian Therapeutic Goods Administration granted marketing ...